ROAM Trial Summary

Last edited 21/02/17 by Priya Francis

Radiation versus Observation following surgical resection of Atypical Meningioma: a randomised controlled trial (The ROAM trial)

 

ROAM is a multi-centre, randomised controlled trial to compare radiotherapy versus active monitoring in patients who have undergone gross total surgical resection (Simpson 1-3) of atypical (grade II) meningioma.

The primary objective of the ROAM trial is to determine whether early adjuvant fractionated external beam radiotherapy reduces the risk of tumour recurrence compared to active monitoring in newly diagnosed atypical meningioma.

 

 Meningiomas comprise 25-33% of adult primary brain tumours. The annual UK incidence of atypical meningioma is 0.2-0.5 / 100,000 / year and ~150 undergo surgical resection each year. Since the publication of the 2000 WHO classification, the reported incidence of atypical meningioma has risen to 20-35%, nevertheless they remain very rare.

 

Benign (grade I) meningioma have a low risk of recurrence (~10% at 5 years) following surgical resection and are managed by active monitoring with MRI scans. Adjuvant radiotherapy is indicated for anaplastic (grade III) meningioma to prolong time to recurrence however 5-year progression free survival is only ~10%.

 

The role of radiotherapy in atypical (grade II) meningioma after gross total resection has not been defined and there is no agreement on the current standard of care for patients with atypical meningioma.

 

Patients with the following characteristics will be eligible for inclusion in the trial:

  • Histologically confirmed newly diagnosed solitary atypical meningioma (WHO grade II) based on the 2016 WHO criteria

  • Age >/= 16 years

  • All anatomical locations allowed except optic nerve sheath tumour

  • Complete resection (Simpson 1, 2 or 3) as assessed by the surgeon

  • Able to commence radiotherapy between within 12 weeks of surgery (ideally 8-12 weeks)

  • WHO performance status 0, 1 or 2

  • Women of reproductive potential must use effective contraception for the whole duration of the treatment

  • Absence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial.

     

      Patients with the following characteristics will be excluded from the trial:

  • Neurofibromatosis type II (NF-2)

  • Optic nerve sheath tumours

  • Multiple meningiomas

  • Radiation-induced meningioma

  • Clinical evidence of second malignancy, except for cervix carcinoma in situ or basal cell carcinoma, and history of invasive malignancy unless treated with curative intent and the patient has not been disease free for the last five years

  • Previous intracranial tumour

  • Pregnant or lactating women

 




I'm fine with this [X]

The site uses cookies, some may have been set already. Please refer to our privacy policy & cookie usage statement.
If you continue to use the site we'll assume you're happy to accept the cookies.